Literature DB >> 20531467

Next-generation model-based drug discovery and development: quantitative and systems pharmacology.

S R B Allerheiligen1.   

Abstract

Pharmaceutical researchers have undertaken many initiatives and technologies to stem the rising costs of drug discovery and development. Biomarkers, adaptive trial designs, modeling, trial simulations, predictive metabolism, data mining, and disease models have reshaped the way in which researchers approach discovery and development. Quantitative pharmacology (QP), which leverages model-based approaches, operates at both cultural and technical levels to integrate data and scientific disciplines so as to utilize existing knowledge while concomitantly enhancing the ability to make predictions about future experiments and results.

Mesh:

Substances:

Year:  2010        PMID: 20531467     DOI: 10.1038/clpt.2010.81

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  21 in total

1.  The influence of distributional kinetics into a peripheral compartment on the pharmacokinetics of substrate partitioning between blood and brain tissue.

Authors:  Jeannie M Padowski; Gary M Pollack
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-09       Impact factor: 2.745

2.  Systems pharmacology identifies drug targets for Stargardt disease-associated retinal degeneration.

Authors:  Yu Chen; Grazyna Palczewska; Debarshi Mustafi; Marcin Golczak; Zhiqian Dong; Osamu Sawada; Tadao Maeda; Akiko Maeda; Krzysztof Palczewski
Journal:  J Clin Invest       Date:  2013-11-15       Impact factor: 14.808

3.  Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator.

Authors:  Xin Zhang; Karen Schneck; Juliana Bue-Valleskey; Kwee Poo Yeo; Michael Heathman; Vikram Sinha
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-22       Impact factor: 2.745

4.  Advancing pharmacometrics and systems pharmacology.

Authors:  S A Waldman; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2012-11       Impact factor: 6.875

Review 5.  Translational PK-PD modeling in pain.

Authors:  Ashraf Yassen; Paul Passier; Yasuhisa Furuichi; Albert Dahan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-30       Impact factor: 2.745

6.  A systems approach for tumor pharmacokinetics.

Authors:  Greg Michael Thurber; Ralph Weissleder
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

Review 7.  Implementation of quantitative and systems pharmacology in large pharma.

Authors:  S A G Visser; D P de Alwis; T Kerbusch; J A Stone; S R B Allerheiligen
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-10-22

8.  Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-Patient Study Designs in Psoriasis.

Authors:  M G Dodds; D H Salinger; J Mandema; J P Gibbs; M A Gibbs
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-07-24

Review 9.  Agent-based modeling: a systematic assessment of use cases and requirements for enhancing pharmaceutical research and development productivity.

Authors:  C Anthony Hunt; Ryan C Kennedy; Sean H J Kim; Glen E P Ropella
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2013-06-04

10.  Differential Gene Expression across Breed and Sex in Commercial Pigs Administered Fenbendazole and Flunixin Meglumine.

Authors:  Jeremy T Howard; Audrey T O'Nan; Christian Maltecca; Ronald E Baynes; Melissa S Ashwell
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.